To include your compound in the COVID-19 Resource Center, submit it here.

Teva to buy Cephalon for $6.8B

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) will acquire cancer and neurology company Cephalon Inc. (NASDAQ:CEPH) for $81.50 per share, or $6.8 billion in

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE